Product Images Alyq

This document appears to be a chart or table displaying information on drug interactions related to CYP3A inhibitors and inducers. The chart outlines the coadministered drugs, including Ritonavi, Ketoconazole, and H2 Antagonists, and the effects they have on CYP3A enzymes. The table also includes recommendations for dose adjustments based on fold changes and 90% Confidence Intervals for each drug interaction.*

Not available. The provided text appears to be a table with no clear headings or context. The output is not readable and contains parts of words and meaningless characters. It is impossible to generate a useful description with the given text.*

This is a chart that shows the mean change from baseline in meters over 16 weeks for a placebo group of 82 people and a group of 79 people taking ALYQ™ 40 mg. The graph shows that there was a significant improvement in the ALYQ™ group compared to the placebo group.*

This is a description of data related to a clinical trial on the use of a medication called ALYQ™ 40 mg for pulmonary arterial hypertension (PAH) in patients with different etiologies, including idiopathic, connective-tissue disease, repaired systemic-to-pulmonary shunts, and others. The data includes information on the baseline 6-minute walk distance, gender, age, and World Health Organization functional class of the subjects, as well as the placebo-adjusted mean change in 6-minute walk distance (in meters) of the medication, with confidence intervals. The text also provides a definition of repaired systemic-to-pulmonary shunts.*

NDC 0093-3334-06 is the product code for ALYQ, which is Tadalafil tablets USP with a strength of 20mg. The rest of the information seems to be batch or serial numbers, and location details which are not relevant for general description.*